Abstract: In an embodiment, the present disclosure pertains to a method of making a composite. In some embodiments, the method includes applying an external magnetic field to a mixture composed of a plurality of magnetic materials in a container, in which the external magnetic field produces a homogenous and uniform magnetic flux in the container. In some embodiments, the method further includes solidifying the mixture to result in the growth of solvent crystals in the mixture, and subliming a solvent phase of the mixture in the container to thereby form a composite having uniformly aligned magnetic materials. In an additional embodiment, the present disclosure pertains to a composite having uniformly aligned magnetic materials. In some embodiments, a majority of the magnetic materials in the composite are aligned in the same direction.

Abstract: Systems and methods for coordinating distributed energy storage in accordance with embodiments of the invention are illustrated. One embodiment includes a power distribution network, including a set of nodes, wherein a node includes a controllable load, an uncontrollable load, and a local controller, a substation connected to each node in the set of nodes by a set of distribution lines, and a global controller including a processor, a memory, and a communications device, wherein the global controller obtains load parameters from at least one node, calculates coordination parameters for each node based on the obtained load parameters, and asynchronously provides the coordination parameters to each of the nodes in the set of nodes, and wherein each node independently obtains coordination parameters, and controls the operation of its controllable load using the local controller based on the coordination parameters and a local load profile describing at least the uncontrollable load.

Abstract: Disclosed is a hormone electrochemical biosensor, e.g. an amperometric biosensor, for the detection of a hormone and measurement of the concentration of a hormone. The disclosed hormone biosensor comprises a hormone-catalyzing enzyme, such as KSDH1. Also described herein are systems comprising an amperometric biosensor, e.g., chronoamperometric biosensor and methods of using the chronoamperometric biosensor.

Abstract: The present disclosure provides compositions and methods of treating motor neuron diseases, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). A modulator of a heat shock protein, such as an Hsp70 family member protein, may be used in the present method. Alternatively, a mutant heat shock protein may be used.

Abstract: A battery electrolyte solution is that includes an organic electrolyte solution, a lithium-sulfur (Li2S) compound, soluble lithium polysulfide (Li2Sx) microparticles, and a redox mediator comprising a soluble quinone derivative.

Abstract: This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.

Abstract: The present disclosure provides variant light-responsive polypeptides, and nucleic acids comprising nucleotide sequences encoding the light-responsive polypeptides. The present disclosure provides methods, devices, and systems for controlling the activity of a cell expressing a variant light-responsive polypeptide of the present disclosure.

Abstract: Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.

Abstract: An acoustic biometric touch scanner device and method is disclosed. In one aspect, an acoustic fingerprint sensing device includes an array of ultrasonic transducers configured to transmit an ultrasound signal having a frequency in a range from 50 megahertz (MHz) to 500 MHz. The acoustic fingerprint ultrasonic transducers include a piezoelectric film. The acoustic fingerprint sensing device further includes a receiving surface configured to receive a finger. The acoustic fingerprint sensing device further includes a processor configured to generate an image of at least a portion of a fingerprint of the finger based on a reflection of the ultrasound signal from the finger.

Abstract: The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the glycosyl-phosphatidylinositol (GPI)-linked GDNF family protein ?-receptor 4 (GFR?4).

Abstract: Methods of deconvolving a feature profile of a physical system are provided herein. The present method may include: optimizing a regression between a) a feature profile of a first plurality of distinct components and b) a reference matrix of feature signatures for a second plurality of distinct components, wherein the feature profile is modeled as a linear combination of the reference matrix, and wherein the optimizing includes solving a set of regression coefficients of the regression, wherein the solution minimizes 1) a linear loss function and 2) an L2-norm penalty function; and estimating the fractional representation of one or more distinct components among the second plurality of distinct components present in the sample based on the set of regression coefficients. Systems and computer readable media for performing the subject methods are also provided.

Abstract: The present invention relates to Charcot-Marie-Tooth disease 2A (CMT2A) harboring the p.Arg364Trp or p.His361Tyr Mfn2 mutation, whose human counterpart results in severe, early-onset axonal neuropathy for p.Arg364Trp Mfn2 mutation in fertilized rat eggs. Cohorts of mutants and wild type littermates were characterized with multiple motor deficits that worsened over time. Separate cohorts of mutant and wild type at 7, 40, and 48 weeks showed reduced density of myelinated axons and active axonal degeneration in distal but not proximal nerves, as well as axonal degeneration in the fasciculus gracilis of the cervical spinal cord at 40 and 48 weeks not present in 7-week-old cohort Mfn2 mutants, or wild type at 7 or 40 weeks. The p.His361Tyr Mfn2 mutation using CRISPR/Cas9 showed abnormalities in gait dynamics at 8 weeks and lengthening of gait cycle at 16 weeks. The invention provides progressive axonal neuropathy for examining pathogenesis and treatment of CMT2A.

Abstract: Provided herein are Cas proteins and guide RNA molecules engineered to exhibit increased activity in eukaryotic cells. The provided Cas proteins and RNA molecules are particularly useful for applications where modulation of eukaryotic nucleic acids with relatively small molecules is advantageous. Also provided are nucleic acids and vectors encoding the disclosed Cas proteins and guide RNA molecules, pharmaceutical compositions including the Cas proteins and guide RNA molecules, and methods for using the disclosed materials.

Abstract: FSP27 compositions and methods for treating cardiovascular diseases are described.

Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R? and IL-2R?. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.

Abstract: The technology described herein is directed to compositions, methods, and systems for measuring the interactions between RNAs and proteins.

Abstract: Provided herein are methods, systems and apparatus for diagnosing, predicting and/or preventing acute allograft vasculopathy in an organ transplant patient. The method comprises executing on a processor the steps comprising: analyzing clinical risk factors of a cardiac, kidney or liver transplant patient in a model which distinguishes between clinical biomarkers of allograft vasculopathy patients and non-allograft vasculopathy patients, and analyzing digital biopsy images from the transplant patient to morphologically differentiate patients which are prE allograft vasculopathy or which have active allograft vasculopathy from patients without acute allograft vasculopathy; assigning prE-, active or non-allograft vasculopathy status to a patient based on the outcome of the analysis of the clinical biomarkers and morphologic biomarkers; and where preE or active statis is assigned, treating the patient.

Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.

Abstract: Methods and compositions are provided for treatment of peroxisomal biogenesis disorders (PBDs). More particularly, recombinant adeno-associated viruses (rAAV) provided in the form of compositions are used to deliver a nucleic acid encoding human PEX1 to host cells. The rAAVs comprise a AAV capsid, and packaged therein a vector genome comprising an AAV 5? inverted terminal repeat (ITR) sequence; a promoter; a coding sequence encoding a human PEX1; and an AAV 3? ITR.

Abstract: Systems and methods for radiology image classification from noisy images in accordance with embodiments of the invention are illustrated. One embodiment includes noisy image classification device, including a processor, camera circuitry, and a memory containing a noisy image classification application, where the noisy image classification application directs the processor to obtain image data describing a first image taken of a second image using the camera circuitry, where the second image was produced by a medical imaging device, and where the first image is a noisy version of the second image, classify the image data using a neural network trained to be robust to noise, generate an investigation recommendation based on the classification, and provide the investigation recommendation via a display.